Chitosan Hemostatic Material: Advanced Formulations, Mechanisms, And Clinical Applications For Rapid Hemorrhage Control

Molecular Composition And Structural Characteristics Of Chitosan Hemostatic Material

Chitosan hemostatic material is fundamentally composed of chitosan polymers—linear polysaccharides consisting of β-(1→4)-linked D-glucosamine and N-acetyl-D-glucosamine units—obtained through alkaline deacetylation of chitin (degree of deacetylation typically 70–95%) 5,11. The primary amine groups (–NH₂) on the glucosamine residues confer a positive charge at physiological pH (pKa ≈ 6.5), enabling strong electrostatic attraction to negatively charged blood components such as red blood cells, platelets, and plasma proteins 1,5. This cationic nature is central to chitosan's hemostatic efficacy, as it promotes rapid aggregation of erythrocytes and activation of the intrinsic coagulation cascade independent of the body's natural clotting factors 6,18.

Key Structural Parameters Influencing Hemostatic Performance:

• Molecular Weight (Mw): High molecular weight chitosan (>100 kDa) forms more robust gel networks upon contact with blood, enhancing mechanical stability of clots 6,14. Microfibrillar high-Mw chitosan textiles treated under nitrogen plasma or γ-irradiation exhibit superior hemostatic activity due to increased surface reactivity and nitrogen incorporation 6.
• Degree Of Deacetylation (DD): Higher DD (>85%) increases the density of free amine groups, amplifying positive charge density and thus electrostatic interactions with blood cells 5,11. However, excessively high DD may reduce solubility in physiological fluids, necessitating salt formation (e.g., chitosan acetate, chitosan succinate) to balance solubility and reactivity 1,5,11.
• Crystallinity And Porosity: Lyophilized chitosan sponges with porosity of 92–97% and pH 5.0–6.5 provide optimal fluid absorption and cell infiltration, facilitating rapid clot formation and tissue integration 8,14. Electrospun chitosan nanofibers with surface density 5–10 g/m² and fiber diameters 100–500 nm maximize surface area for blood contact, accelerating hemostasis 8,15.

Chemical Modifications For Enhanced Functionality:

• Chitosan Salts: Chitosan acetate 1, chitosan lactate 1, chitosan succinate 5,11, chitosan malate 1, and chitosan acrylate 1 are water-soluble derivatives that dissolve in blood to form viscous gels, stemming blood flow without generating exothermic reactions (unlike zeolite-based agents such as QuikClot) 5,11. Chitosan succinate, in particular, demonstrates rapid gelation (within 2–3 minutes) and mild antibacterial activity, reducing infection risk at wound sites 5,10,11.
• O,O'-Dipalmitoylchitosan: This lipophilic derivative incorporates fatty acid hydrocarbon radicals (C10–C18) linked via amino groups, enhancing bioadhesion and clot stability under mechanical stress 4. When combined with neutral bioadhesive substances and surfactants, O,O'-dipalmitoylchitosan-based hemostatic agents achieve stable clot formation even in field conditions, with reduced risk of bleeding recurrence 4.
• Carboxymethyl Chitosan (CMCS): CMCS coatings on chitosan nonwoven fabrics improve hydrophilicity and cell adhesion, promoting effective hemostasis in cervical biopsies and gynecological surgeries 9. CMCS sponges integrated into tampon-type hemostatic devices provide targeted compression and fluid absorption, preventing excessive bleeding in anatomically complex sites 9.

Hemostatic Mechanisms And Coagulation Cascade Activation

Chitosan hemostatic material operates through multiple synergistic mechanisms that collectively accelerate blood clot formation and stabilize hemostasis:

Electrostatic Aggregation Of Blood Cells

The cationic amine groups of chitosan interact electrostatically with negatively charged erythrocyte membranes (due to sialic acid residues) and platelet surfaces, inducing rapid cell aggregation and formation of a physical barrier at the bleeding site 1,5,18. This aggregation occurs within seconds of chitosan contact with blood, independent of the intrinsic or extrinsic coagulation pathways, making chitosan effective even in coagulopathic patients (e.g., hemophiliacs) 10,11.

Activation Of The Intrinsic Coagulation Pathway

Chitosan activates Factor XII (Hageman factor) upon contact, initiating the intrinsic coagulation cascade and leading to thrombin generation and fibrin polymerization 6,18. Microfibrillar chitosan textiles treated under nitrogen plasma exhibit enhanced Factor XII activation due to increased surface nitrogen content and reactive functional groups 6. This mechanism complements the electrostatic aggregation, resulting in robust clot formation with tensile strength sufficient to withstand physiological blood pressure (systolic pressure up to 120 mmHg) 14,17.

Gel Formation And Physical Barrier Creation

Water-soluble chitosan salts dissolve in blood to form viscous hydrogels that physically occlude bleeding vessels and capillaries 5,11,18. The gelation kinetics depend on chitosan concentration (typically 2.0–7.0 wt% in formulation solutions) 8, molecular weight, and ionic strength of the blood environment. Chitosan succinate gels achieve hemostasis within 2–3 minutes of application, with gel viscosity (η₀) in the range of 0.1–0.4 Pa·s and surface tension 40–50 mN/m, optimizing spreadability and adhesion to wound surfaces 8,10.

Platelet Activation And Aggregation

Chitosan promotes platelet adhesion and activation through integrin receptor binding and release of platelet-derived growth factors (PDGF) and transforming growth factor-β (TGF-β), which further stimulate coagulation and wound healing 6,14. Crosslinked chitosan matrices with hygroscopic plasticizers (e.g., glycerol, sorbitol) maintain flexibility when exposed to moisture, ensuring sustained platelet contact and clot stability during patient movement 14,17.

Antibacterial Activity And Infection Prevention

Chitosan exhibits intrinsic antibacterial properties by disrupting bacterial cell membranes and chelating essential metal ions (e.g., Fe²⁺, Zn²⁺) required for microbial metabolism 5,10,11. Chitosan-based hemostatic materials incorporating nano-silver particles (10–50 nm diameter) demonstrate enhanced bacteriostatic and anti-inflammatory effects, reducing wound infection rates by >90% compared to conventional gauze dressings 15,16. The combination of chitosan with medicinal plant extracts (e.g., Jatropha molissima) further augments antibacterial efficacy and promotes tissue regeneration 16.

Formulation Strategies And Manufacturing Processes For Chitosan Hemostatic Material

Powder And Granular Formulations

Chitosan hemostatic powders comprise chitosan salts (e.g., chitosan succinate) combined with inert materials (e.g., calcium carbonate, silica) to improve flowability and storage stability 5,11. The powder formulation allows rapid application by personnel with minimal training, as it can be poured directly onto bleeding wounds without requiring precise placement 5,11. The chitosan salt dissolves in blood to form a gel, stemming blood flow within 2–3 minutes, and the inert filler provides structural support to prevent powder dispersion 5,11.

Manufacturing Process:

1. Chitosan Salt Synthesis: Chitosan is reacted with organic acids (e.g., succinic acid, acetic acid) in aqueous solution at room temperature (20–25°C) to form water-soluble chitosan salts 5,8,11. The reaction is typically conducted at a chitosan:acid molar ratio of 1:1 to 1:2, with stirring for 2–4 hours until complete dissolution 8.
2. Blending With Inert Materials: The chitosan salt solution is mixed with inert powders (e.g., calcium carbonate at 10–30 wt%) to achieve desired flowability and prevent caking during storage 5,11.
3. Spray Drying Or Lyophilization: The blended solution is spray-dried at inlet temperature 120–150°C and outlet temperature 60–80°C to obtain fine powder (particle size 10–100 μm) 5,11. Alternatively, lyophilization (freeze-drying) at −40°C under vacuum (<0.1 mbar) produces porous granules with high surface area for rapid blood absorption 8,14.
4. Sterilization: The powder is sterilized by γ-irradiation (25–50 kGy) or ethylene oxide (EtO) treatment to ensure microbial safety without compromising chitosan's hemostatic activity 6,11.

Sponge And Foam Formulations

Chitosan sponges are three-dimensional porous matrices with porosity 92–97% and pore diameters 50–300 μm, designed for high fluid absorption (up to 20× their dry weight) and rapid clot formation 8,14. These sponges are particularly effective for deep, narrow, or irregularly shaped wounds where powder application is impractical 2,3,10.

Manufacturing Process:

1. Solution Preparation: Chitosan (2.0–7.0 wt%) is dissolved in aqueous organic acid solution (e.g., 20–60 wt% acetic acid) with plasticizing additives (0.05–0.5 wt% glycerol or sorbitol) to achieve specific electrical conductivity (σ) of 4.0–5.0 mS/cm and zero-shear viscosity (η₀) of 0.1–0.4 Pa·s 8.
2. Rapid Freezing: The chitosan solution is poured into molds and rapidly frozen at −80°C to form ice crystals that template the porous structure 8,14.
3. Lyophilization: The frozen solution is placed under vacuum (<0.1 mbar) at −40°C for 24–48 hours to sublimate ice, leaving a porous chitosan sponge 8,14.
4. Crosslinking And Curing: The dried sponge is cured at 60–80°C and 25–35% relative humidity for 4–12 hours to crosslink ≥25% of chitosan polymers via Maillard-type reactions or multifunctional organic acid (e.g., citric acid) crosslinking, enhancing structural stability and resistance to dissolution in blood 14,17.
5. Sterilization And Packaging: The sponge is sterilized by γ-irradiation (25–50 kGy) and packaged in moisture-barrier pouches to maintain dryness and rigidity until use 14,17.

Textile And Nonwoven Fabric Formulations

Chitosan-based hemostatic textiles are fabricated from microfibrillar chitosan fibers or electrospun nanofibers, offering flexibility, conformability, and ease of application as bandages, gauze pads, or wound dressings 6,7,9,15.

Manufacturing Process:

1. Electrospinning: Chitosan solution (2.0–7.0 wt% in aqueous acetic acid with 0.05–0.5 wt% plasticizer) is electrospun at 90–110 kV voltage, 120–170 mm electrode distance, 20–25°C chamber temperature, and 25–35% relative humidity to produce nanofibers (diameter 100–500 nm) with surface density 5–10 g/m² 8,15. The nanofibers are chaotically deposited on a grounded substrate to form a nonwoven fabric 8,15.
2. Nitrogen Plasma Treatment: The chitosan textile is treated under nitrogen plasma (RF power 100–300 W, pressure 0.1–1.0 mbar, treatment time 5–30 minutes) to ionize nitrogen and incorporate reactive nitrogen species into the chitosan structure, enhancing hemostatic activity and antibacterial properties 6.
3. Coating With CMCS Or Nano-Silver: The textile is coated with carboxymethyl chitosan (CMCS) solution (1–5 wt%) or nano-silver suspension (0.01–0.1 wt% Ag nanoparticles) by dip-coating or spray-coating, followed by drying at 40–60°C for 2–4 hours 9,15. CMCS coating improves hydrophilicity and cell adhesion, while nano-silver enhances antibacterial efficacy 9,15.
4. Sterilization And Packaging: The coated textile is sterilized by γ-irradiation (25–50 kGy) and packaged in sterile pouches for clinical use 6,9,15.

Spray Formulations

Chitosan hemostatic sprays comprise native chitosan particles (10–100 μm diameter) at least partially coated with chitosan salts (e.g., chitosan acetate, chitosan succinate), suspended in a propellant (e.g., compressed air, nitrogen) for aerosol delivery 18. The spray formulation enables rapid and uniform application on complex wound architectures (e.g., blast injuries, lacerations with irregular edges) and achieves hemostasis within 1–2 minutes with minimal blood loss 18.

Manufacturing Process:

1. Chitosan Particle Preparation: Native chitosan is milled to particle size 10–100 μm and coated with chitosan salt solution (1–5 wt%) by fluid-bed coating or spray-drying 18.
2. Suspension In Propellant: The coated chitosan particles are suspended in sterile saline (0.9% NaCl) or phosphate-buffered saline (PBS, pH 7.4) at 5–20 wt% concentration, and the suspension is filled into aerosol canisters with compressed air or nitrogen propellant (pressure 2–5 bar) 18.
3. Sterilization: The filled canisters are sterilized by γ-irradiation (25–50 kGy) or autoclaving (121°C, 15 minutes) to ensure microbial safety 18.

Performance Benchmarks And Quantitative Hemostatic Efficacy

Bleeding Time Reduction

Chitosan hemostatic materials achieve significant reductions in bleeding time across various wound models:

• Chitosan Succinate Powder: In a rat femoral artery injury model, chitosan succinate powder reduced bleeding time from 8.5 ± 1.2 minutes (control gauze) to 2.3 ± 0.5 minutes (p < 0.001), representing a 73% reduction 5,11.
• Chitosan Sponge: In a rabbit liver laceration model, chitosan sponge achieved hemostasis in 3.1 ± 0.7 minutes compared to 9.8 ± 1.5 minutes for standard gauze (p < 0.001), with 68% reduction in bleeding time 8,14.
• Chitosan Hemostatic Spray: In a swine femoral artery hemorrhage model, chitosan spray reduced bleeding time to 1.8 ± 0.4 minutes versus 7.2 ± 1.1 minutes for Celox powder (p < 0.001) and 6.5 ± 0.9 minutes for QuikClot gauze (p < 0.001), demonstrating superior performance 18.

Blood Loss Volume Reduction

Chitosan hemostatic materials significantly reduce total blood loss volume:

• Chitosan Succinate Powder: In a rat femoral artery injury model, blood